Table 3.
Physicochemical and pharmacokinetic properties of the studied ligands.
| cpd | MW | PSA | Rule of Five | % h Oral Abs | QPP Caco |
QP logBB |
QP logHERG |
|---|---|---|---|---|---|---|---|
| 9c | 297.371 | 95.123 | 0 | 76.996 | 209.196 | −1.454 | −4.882 |
| 10a | 257.35 | 89.372 | 0 | 60.538 | 67.277 | −1.064 | −5.688 |
| 12c | 331.389 | 93.581 | 0 | 80.227 | 228.807 | −1.242 | −5.54 |
| 14b | 384.247 | 111.98 | 0 | 72.068 | 134.213 | −1.639 | −6.072 |
| AAZ | 222.236 | 133.243 | 0 | 44.375 | 35.654 | −1.802 | −3.791 |
MW: molecular weight; PSA: Van der Waals surface area of polar nitrogen and oxygen atoms and carbonyl carbon atoms (7–200); Rule Of Five: Number of violations of Lipinski rule of five; h Oral Abs: human oral absorption (1, 2, or 3 for low, medium, or high); % h OralAbs: Predicted human oral absorption on a 0–100% scale; QPPCaco: Predicted apparent Caco-2 cell permeability in nm/s. Caco-2 cells are a model for the gut–blood barrier (500 great); QPlogBB: Predicted brain/blood partition coefficient (−3.0 to 1.2); QPlogHERG: Predicted IC50 value for the blockage of HERG K+ channels (concern below −5).